Skip to main content
    A

    Amicus Therapeutics Inc (FOLD)

    Official site

    BIOTECHNOLOGY

    $14.49
    +0.00 (+0.00%)

    Last updated: Apr 27, 2026 at 5:00 PM ET

    Amicus Therapeutics Inc (FOLD) Financials: Revenue, Profit and Cash Flow

    Updated Feb 19, 2026. Financial statements from company filings, amounts in US dollars.

    Amicus Therapeutics reported revenue of $634.21M for the fiscal year ended Dec 31, 2025, up 20.0% from the year before. That year, net income was -$27.11M with a net margin of -4.3%, operating cash flow was $33.15M and free cash flow was $29.85M. The quarter ended Dec 31, 2025 had revenue of $185.21M and net income of $1.69M.

    Revenue and Margins

    The operating margin was 5.2% in the fiscal year ended Dec 2025, the highest of the 6 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $4.96M, a compound annual rate of 71.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$634.21M+20.0%88.5%5.2%-4.3%
    Dec 2024$528.29M+32.3%90.0%4.7%-10.6%
    Dec 2023$399.36M+21.3%90.7%-19.3%-38.0%
    Dec 2022$329.23M+7.8%88.3%-64.4%-71.9%
    Dec 2021$305.51M+17.1%88.7%-67.6%-82.0%
    Dec 2020$260.89M+43.2%88.1%-94.7%-106.1%
    Dec 2019$182.24M+99.7%87.9%-166.8%-195.6%
    Dec 2018$91.25M+147.1%84.2%-360.3%-382.5%
    Dec 2017$36.93M+644.9%83.1%-1196.8%-769.0%
    Dec 2016$4.96MN/A83.2%-3668.6%-4034.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, net income fell 88.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$634.21M$528.29M$399.36M$329.23M$305.51M$260.89M$182.24M$91.25M$36.93M$4.96M
    Cost of revenue$72.93M$52.94M$37.33M$38.60M$34.47M$31.04M$21.96M$14.40M$6.24M$833.00K
    Gross profit$561.28M$475.35M$362.03M$290.63M$271.05M$229.84M$160.27M$76.84M$30.69M$4.13M
    Research and development$135.84M$109.36M$152.38M$276.68M$272.05M$308.44M$286.38M$270.90M$149.31M$104.79M
    Operating income$32.79M$24.88M-$77.21M-$212.12M-$206.43M-$247.00M-$304.04M-$328.78M-$441.99M-$181.89M
    Net income-$27.11M-$56.11M-$151.58M-$236.57M-$250.46M-$276.85M-$356.39M-$349.00M-$284.00M-$200.04M
    EBITDA$53.06M$26.24MN/A-$199.97M-$200.64M-$244.41MN/A-$322.47M-$422.68MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue$185.21M$169.06M$154.69M$125.25M$149.71M$141.52M$126.67M$110.40M$115.08M$103.50M$94.50M$86.27M
    Gross profit$158.66M$149.59M$139.47M$113.55M$134.87M$128.24M$115.41M$96.84M$103.76M$93.56M$85.39M$79.33M
    Operating income$15.95M$34.27M-$9.47M-$7.95M$15.97M$21.66M$14.97M-$27.72M-$3.69M-$17.02M-$18.86M-$37.64M
    Net income$1.69M$17.31M-$24.42M-$21.69M$14.74M-$6.73M-$15.70M-$48.42M-$33.84M-$21.58M-$43.23M-$52.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $401.40M exceeded cash and equivalents by $187.39M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$949.87M$785.03M$777.88M$724.17M$905.14M$886.52M$850.21M$789.95M$627.02M$1.04B
    Current assets$676.17M$504.74M$483.06M$423.82M$596.83M$579.47M$520.07M$551.10M$391.96M$340.06M
    Cash and equivalents$214.01M$213.75M$246.99M$148.81M$245.20M$163.24M$142.84M$79.75M$49.06M$187.03M
    Total liabilities$675.63M$590.99M$617.71M$601.12M$597.77M$600.14M$373.78M$447.04M$274.17M$676.69M
    Short-term debt$8.74M$8.46M$8.32M$21.42M$18.90M$8.90M$0N/A$8.40M$56.10M
    Long-term debt$392.66M$390.11M$387.86M$391.99M$389.36M$389.25M$149.50M$321.74M$164.17M$154.46M
    Shareholder equity$274.24M$194.04M$160.17M$123.05M$307.37M$286.38M$476.43M$342.91M$352.85M$360.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets$949.87M$868.81M$815.30M$789.84M$785.03M$786.56M$749.48M$721.79M$777.88M$764.08M$730.09M$700.52M
    Total liabilities$675.63M$638.39M$611.00M$596.28M$590.99M$607.73M$616.96M$591.10M$617.71M$630.85M$618.51M$597.95M
    Cash and equivalents$214.01M$190.55M$158.70M$181.66M$213.75M$233.65M$209.34M$209.76M$246.99M$263.32M$211.31M$160.60M
    Shareholder equity$274.24M$230.42M$204.30M$193.56M$194.04M$178.82M$132.52M$130.69M$160.17M$133.24M$111.58M$102.57M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 90.0% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$33.15M-$33.89M-$69.09M-$166.57M-$202.49M-$233.29M-$250.42M-$299.95M-$213.69M-$150.15M
    Capital expenditures$3.30M$3.55M$7.44M$3.77M$3.88M$3.23M$20.01M$6.31M$4.53M$5.95M
    Free cash flow$29.85M-$37.44M-$76.53M-$170.34M-$206.38M-$236.52M-$270.43M-$306.26M-$218.22M-$156.10M
    Dividends paidN/AN/AN/A$4.31M$15.01M$32.25M$3.23MN/A$0$0
    Investing cash flow-$46.43M-$560.00K$98.06M$92.32M$78.76M-$13.58M$95.15M-$121.20M-$171.24M-$4.51M
    Financing cash flow$610.00K$5.12M$61.68M-$7.46M$212.07M$262.86M$217.50M$450.77M$247.43M$272.71M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow$16.25M$35.66M-$26.53M$7.76M-$3.92M-$22.97M$22.69M-$29.70M$3.46M-$38.35M-$16.13M-$18.07M
    Capital expenditures$299.00K$382.00K$2.40M$212.00K$288.00K$266.00K$1.19M$1.81M$1.73M$1.56M$2.20M$1.94M
    Free cash flow$15.95M$35.28M-$28.93M$7.55M-$4.20M-$23.24M$21.50M-$31.51M$1.73M-$39.91M-$18.34M-$20.01M
    Last 12 quarters

    Frequently Asked Questions About FOLD

    What is Amicus Therapeutics' annual revenue?

    Amicus Therapeutics reported revenue of $634.21M for the fiscal year ended Dec 31, 2025.

    How fast is Amicus Therapeutics' revenue growing?

    Revenue was up 20.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 24.4%.

    Is Amicus Therapeutics profitable?

    No. Amicus Therapeutics reported net income of -$27.11M for the fiscal year ended Dec 31, 2025, with a net margin of -4.3%.

    How much free cash flow does FOLD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $33.15M minus capital expenditures of $3.30M produced free cash flow of $29.85M.

    How much debt does Amicus Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $392.66M, short-term debt of $8.74M and cash and equivalents of $214.01M.